The Journal of Clinical Endocrinology & Metabolism · 2002 · 53 citations · 27 references
MedicineEndocrinologyGeneticsEndocrine GeneticsNeuroendocrinologyNeurogeneticsCongenital Endocrine DisordersDiabetes MellitusDisease MechanismsGenetic DisordersNeurogenetic DisordersPituitary Disorder GeneticsDiabetes Insipidus SyndromesFamilial SyndromesMissense MutationsMutationPosterior Pituitary Hormone ReleasePosterior Pituitary HormonesSignal Peptide MotifVasopressin Release
The autosomal dominant form of familial neurohypophyseal diabetes insipidus (adFNDI) has been linked to 40 different mutations of the gene encoding the vasopressin-neurophysin II (AVP-NPII) precursor. All of these mutations have been located in either the signal peptide or neurophysin II moiety. We now report a three-generation Turkish kindred in which severe adFNDI cosegregates with a novel missense mutation in the part of the AVP-NPII gene encoding the AVP moiety. This mutation (T-->C at position 285 in the genomic sequence) was found in only one allele and predicts a substitution of histidine for tyrosine at position 2 in AVP. Like other adFNDI mutations, this substitution is expected to impair folding and processing of the precursor, in this case by interfering with normal binding of the AVP and NPII moieties. It is associated clinically with inability to concentrate urine during fluid deprivation, a greater than 80% deficiency of AVP secretion, and absence of the posterior pituitary bright spot on magnetic resonance imaging. These findings are consistent with the hypothesis that mutations in the AVP-NPII gene cause adFNDI by directing the production of a folding incompetent precursor that prevents the expression of the normal allele via a cytotoxic effect on the magnocellular neurons.
27
Masaki Ito, J. Larry Jameson, Masaki Ito · Journal of Clinical Investigation · 1997 · 173 citations · Full text
Long‐Qing Chen, J.P. Rose, Esther Breslow et al. · Proceedings of the National Academy of Sciences · 1991 · 142 citations